DK0842161T3 - 4,5-diaryl-oxazol-derivater - Google Patents

4,5-diaryl-oxazol-derivater

Info

Publication number
DK0842161T3
DK0842161T3 DK96924137T DK96924137T DK0842161T3 DK 0842161 T3 DK0842161 T3 DK 0842161T3 DK 96924137 T DK96924137 T DK 96924137T DK 96924137 T DK96924137 T DK 96924137T DK 0842161 T3 DK0842161 T3 DK 0842161T3
Authority
DK
Denmark
Prior art keywords
oxazole derivatives
carboxy
diaryl oxazole
diaryl
alkylphenyl
Prior art date
Application number
DK96924137T
Other languages
Danish (da)
English (en)
Inventor
Kiyoshi Taniguchi
Kouji Hattori
Kazunori Tsubaki
Osamu Okitsu
Seiichiro Tabuchi
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515085.0A external-priority patent/GB9515085D0/en
Priority claimed from AUPN9002A external-priority patent/AUPN900296A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of DK0842161T3 publication Critical patent/DK0842161T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK96924137T 1995-07-21 1996-07-18 4,5-diaryl-oxazol-derivater DK0842161T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9515085.0A GB9515085D0 (en) 1995-07-21 1995-07-21 Heterocyclic compounds
AUPN9002A AUPN900296A0 (en) 1996-03-29 1996-03-29 Heterocyclic compounds
PCT/JP1996/001996 WO1997003973A1 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives

Publications (1)

Publication Number Publication Date
DK0842161T3 true DK0842161T3 (da) 2003-01-27

Family

ID=25645150

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96924137T DK0842161T3 (da) 1995-07-21 1996-07-18 4,5-diaryl-oxazol-derivater

Country Status (17)

Country Link
US (2) US5972965A (de)
EP (2) EP1213285A3 (de)
JP (1) JPH11509191A (de)
KR (1) KR19990063582A (de)
CN (1) CN1095839C (de)
AT (1) ATE224380T1 (de)
AU (1) AU716304B2 (de)
CA (1) CA2227442A1 (de)
DE (1) DE69623785T2 (de)
DK (1) DK0842161T3 (de)
EA (1) EA002156B1 (de)
ES (1) ES2181902T3 (de)
HU (1) HUP9900881A3 (de)
MX (1) MX9800577A (de)
PT (1) PT842161E (de)
TW (1) TW401408B (de)
WO (1) WO1997003973A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AUPP003297A0 (en) * 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPP029197A0 (en) 1997-11-10 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. Benzocycloheptene derivatives
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives
DE19801648A1 (de) * 1998-01-17 1999-07-22 Bayer Ag alpha-Substituierte Lactone
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
MXPA01008955A (es) 1999-03-05 2002-04-24 Procter & Gamble Analogos de prostaglandinas selectivas de fp no saturadas de c16.
KR20020015345A (ko) * 1999-06-21 2002-02-27 후지야마 아키라 피부 궤양 치료제
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20040116530A1 (en) * 2001-04-18 2004-06-17 Noriaki Maeda Tissue fibrosis inhibitors
DE60233043D1 (de) 2001-04-19 2009-09-03 Eisai R&D Man Co Ltd 2-iminoimidazolderivate
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
NZ535748A (en) * 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
EP1591443B1 (de) 2003-02-07 2010-08-25 Daiichi Sankyo Company, Limited Pyrazolderivat
AU2004218187C1 (en) 2003-02-19 2011-04-07 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
US7557095B2 (en) * 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
ES2532858T3 (es) 2008-07-23 2015-04-01 Toray Industries, Inc. Agente terapéutico para insuficiencia renal crónica
EP2343292B1 (de) 2008-09-10 2014-08-06 Asahi Glass Company, Limited Neues prostaglandin-i2-derivat
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
ES2593229T3 (es) * 2010-03-08 2016-12-07 Kaken Pharmaceutical Co., Ltd. Nuevo agonista de EP4
US8653118B2 (en) 2010-08-20 2014-02-18 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
EP2888253A4 (de) * 2012-08-24 2016-01-06 Univ Texas Heterocyclische hif-aktivitätsmodulatoren zur behandlung von krankheiten
US20140073634A1 (en) * 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
DK2888255T3 (en) 2012-08-24 2018-10-29 Univ Texas HETOCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
EP3110420B8 (de) * 2014-02-25 2019-07-10 Board of Regents, The University of Texas System Salze von heterocyclischen modulatoren der hif-aktivität zur behandlung von krankheiten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236474A (en) * 1989-12-20 1993-07-27 Bristol Myers Squibb Co 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
PT736018E (pt) * 1993-12-20 2000-10-31 Fujisawa Pharmaceutical Co Derivados de 4,5-diariloxazol
CN1057522C (zh) 1994-03-10 2000-10-18 藤泽药品工业株式会社 作为前列腺素i2激动剂的萘衍生物

Also Published As

Publication number Publication date
HUP9900881A3 (en) 2000-09-28
DE69623785D1 (de) 2002-10-24
AU716304B2 (en) 2000-02-24
TW401408B (en) 2000-08-11
EP1213285A2 (de) 2002-06-12
WO1997003973A1 (en) 1997-02-06
EP1213285A3 (de) 2002-07-03
JPH11509191A (ja) 1999-08-17
PT842161E (pt) 2003-02-28
CN1196726A (zh) 1998-10-21
ES2181902T3 (es) 2003-03-01
EA199800141A1 (ru) 1998-08-27
MX9800577A (es) 1998-04-30
DE69623785T2 (de) 2003-08-07
ATE224380T1 (de) 2002-10-15
CA2227442A1 (en) 1997-02-06
KR19990063582A (ko) 1999-07-26
CN1095839C (zh) 2002-12-11
US5972965A (en) 1999-10-26
AU6469796A (en) 1997-02-18
EP0842161B1 (de) 2002-09-18
US6300344B1 (en) 2001-10-09
EA002156B1 (ru) 2001-12-24
HUP9900881A2 (hu) 1999-08-30
EP0842161A1 (de) 1998-05-20

Similar Documents

Publication Publication Date Title
DK0842161T3 (da) 4,5-diaryl-oxazol-derivater
NO911231D0 (no) Fremgangsmaate for fremstilling av 3,5-di-tert. butyl-4-hydroksyfenylmetylen-derivater av 2-substituerte tiazolidinoner, oksazolidinoner og imidazolidinoner.
FI924397A (fi) Substituerade pyrimidiner
DE69108138D1 (de) Imidazopyridinderivate und ihre Verwendung.
NO180407C (no) Anvendelse av 1,3-oksatiolannukleosidanaloger ved fremstilling av et medikament for behandling av hepatitt B
ATE171068T1 (de) Chinoloncarbonsäurederivate, ihre herstellung und ihre verwendung als zelladhäsion inhibitoren
DK0444659T3 (da) Farmaceutisk opløsning indeholdende derivater af FK 506
ES2093041T3 (es) Derivados de 2-oxo-(1,8-naftiridina).
DE69406323T2 (de) Substituierte Aminsäure Derivate verwendbar für die Behandlung von Arteriosclerosis
PT916651E (pt) DERIVADOS DE áCIDO FENILALQUILCARBOXILICO
FI883584A (fi) Foerfarande foer framstaellning av 2'-deoxi-5-fluorouridins derivat.
FI913506A (fi) Foerfarande foer framstaellning av 6-(substituerat aminopropionyl)-derivat av forskolin.
DK0534655T3 (da) Thiazolidin-2,4-dioner til behandling af hypertension
NO306302B1 (no) FremgangsmÕte for fremstilling av krystallinsk loracarbef-monohydrat
ATE125790T1 (de) N-fumaramidsäurederivate und diese enthaltende fungizide.